Sugi Predict

Sugi Predict / Compounds / SCHEMBL214593

SCHEMBL214593

SCHEMBL214593

CC(C)(C)OC(=O)N1CCN(CCCO)CC1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ ACKR3 P25106 4/20 0.47
▸ TLR8 Q9NR97 1/20 0.46
▸ CHRM2 P08172 2/20 0.46
▸ CHRM1 P11229 2/20 0.46
▸ CHRM4 P08173 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ EPHX2 P34913 3/20 0.43
▸ ESRRB O95718 1/20 0.43
▸ ESR1 P03372 1/20 0.43
▸ ESRRA P11474 1/20 0.43
▸ ESRRG P62508 1/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12193455 0.95 USP2 (0.47) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL27317678 0.94 MEN1 (0.46) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL1715344 0.94 USP2 (0.46) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL28536701 0.94 USP2 (0.46) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL25507694 0.94 USP2 (0.46) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL25507301 0.94 USP2 (0.46) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL20873847 0.91 USP2 (0.53) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL39756 0.90 USP2 (0.51) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL8253901 0.90 USP2 (0.51) USP2SMN1; SMN2ACKR3TLR8CHRM2
SCHEMBL27097884 0.90 EPHX2 (0.44) USP2SMN1; SMN2ACKR3TLR8CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 — — CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 — — US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 — — EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 — — CN claimed
US-12637480-B2 Heterocyclic compounds as sting modulators BEONE MEDICINES I GMBH (CH) 2026-05-26 — — US disclosed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-12594264-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-04-07 — — US disclosed
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-02 — — US disclosed
US-12583818-B2 Compound, preparation method thereof, and use thereof DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2026-03-24 — — US disclosed
US-12552775-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2026-02-17 — — US disclosed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
US-20250320216-A1 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF TOPADUR PHARMA AG (CH) 2025-10-16 — — US disclosed
CN-1343201-A Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them BOEHRINGER INGELHEIM PHARMA (DE) 2002-04-03 — — CN disclosed
WO-2002016352-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 — — WO disclosed
EP-1163227-A1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM Boehringer Ingelheim Pharma KG (DE) 2001-12-19 — — EP disclosed
WO-2001094341-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS ASTRAZENECA AB (SE) 2001-12-13 — — WO disclosed
EP-1157011-A1 4-AMINO- QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES Boehringer Ingelheim Pharma KG (DE) 2001-11-28 — — EP disclosed
WO-2000055141-A1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-21 — — WO disclosed
WO-2000051991-A1 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-08 — — WO disclosed
US-5086051-A 1H, 3H-pyrrolo[1,2-c]thiazole-7-carboxamide derivatives and pharmaceutical compositions containing them RHONE-POULENC SANTE (FR) 1992-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583818-B2 Compound, preparation method thereof, and use thereof TYRO3, TH, SRMS USP2 4057/4885SMN1; SMN2 1810/4885ACKR3 1167/4885
US-12552775-B2 Compounds and uses thereof SMARCC1, SMARCC2, CHD1 USP2 2985/4885SMN1; SMN2 238/4885ACKR3 4297/4885
US-20250320216-A1 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF PDE7A, PDE3A, PDE3B USP2 2992/4885SMN1; SMN2 3935/4885ACKR3 979/4885
US-12594264-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ADRM1, CRBN, SNCA USP2 35/4885SMN1; SMN2 306/4885ACKR3 4351/4885
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF BCL2L2, BCL2A1, BCL2L1 USP2 1066/4885SMN1; SMN2 744/4885ACKR3 3991/4885
US-12637480-B2 Heterocyclic compounds as sting modulators STING1, IFNAR1, IRF3 USP2 3630/4885SMN1; SMN2 2175/4885ACKR3 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.